Myriad Genetics (NASDAQ: MYGN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Myriad Genetics Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Myriad Genetics Company Info
Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.
News & Analysis
But there were a few encouraging signs for the molecular-diagnostics company.
Coronavirus testing is up, but the pandemic has hammered demand for Myriad's hereditary cancer tests.
Have these growth stocks bottomed out? That's probably the wrong question to ask.
More babies are born in summer and early fall than other times of year, meaning mothers-to-be are likely undergoing prenatal testing now. Can investors profit?
The molecular diagnostics company also delivered an earnings miss, and its stock plunged.
The molecular diagnostics company's latest quarterly results weren't anywhere close to what Wall Street expected.
Poor earnings took many stocks lower Tuesday.
The genetic-testing leader just whacked its fiscal full-year 2020 guidance.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
MYGN earnings call for the period ending September 30, 2021.
MYGN earnings call for the period ending June 30, 2021.
MYGN earnings call for the period ending December 31, 2020.
MYGN earnings call for the period ending September 30, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.